Drug Information

Drug General Information
Drug ID
D05FXD
Former ID
DIB019563
Drug Name
compound 66
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530413]
Formula
C22H19N5O4
InChI
InChI=1S/C22H19N5O4/c1-12-8-9-13(28)10-14(12)16-11-26-18-19(25(2)22(30)24-20(18)29)23-21(26)27(16)15-6-4-5-7-17(15)31-3/h4-11,28H,1-3H3,(H,24,29,30)
InChIKey
JTWMOWRMSZZHDR-UHFFFAOYSA-N
PubChem Compound ID
44478401
PubChem Substance ID
85759403, 97100131, 103697953, 104140747, 144073950, 172915285, 180413098, 249565821
Target and Pathway
Target(s) EPH receptor A7 Target Info Inhibitor [530413]
EPH receptor B1 Target Info Inhibitor [530413]
Ephrin type-B receptor 2 Target Info Inhibitor [530413]
Epha4 tyrosine kinase receptor Target Info Inhibitor [530413]
EPH receptor B3 Target Info Inhibitor [530413]
Epha3 tyrosine kinase receptor Target Info Inhibitor [530413]
EPH receptor A5 Target Info Inhibitor [530413]
Ephrin type-B receptor 4 Target Info Inhibitor [530413]
EPH receptor A8 Target Info Inhibitor [530413]
EPH receptor A1 Target Info Inhibitor [530413]
Ephrin type-A receptor 2 Target Info Inhibitor [530413]
KEGG Pathway Axon guidancehsa04360:Axon guidancehsa04360:Axon guidancehsa04360:Axon guidancehsa04014:Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Axon guidance
NetPath Pathway IL2 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
PANTHER Pathway Angiogenesis
Pathway Interaction Database EPHB forward signaling
EphrinB-EPHB pathway
Syndecan-2-mediated signaling events
Ephrin B reverse signalingephrina_ephapathway:EphrinA-EPHA pathway
EPHA forward signalingephrina_ephapathway:EphrinA-EPHA pathway
EPHA forward signalingephbfwdpathway:EPHB forward signaling
Arf6 signaling events
Direct p53 effectors
EPHA forward signaling
Stabilization and expansion of the E-cadherin adherens junction
EPHA2 forward signaling
Reactome EPH-Ephrin signaling
L1CAM interactions
EPHB-mediated forward signaling
EPH-ephrin mediated repulsion of cellsR-HSA-2682334:EPH-Ephrin signaling
EPHA-mediated growth cone collapse
EPH-ephrin mediated repulsion of cells
WikiPathways Transcriptional activation by NRF2
NLR Proteins
Regulation of Microtubule Cytoskeleton
L1CAM interactionsWP2854:Gene regulatory network modelling somitogenesis
Spinal Cord InjuryWP2884:NRF2 pathwayWP2877:Vitamin D Receptor PathwayWP2884:NRF2 pathway
References
Ref 530413Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
Ref 530413Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.